Company Quick10K Filing
Vitality Biopharma
10-Q 2019-12-31 Filed 2020-02-14
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-13
10-K 2019-03-31 Filed 2019-07-15
10-Q 2018-12-31 Filed 2019-02-14
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-14
10-K 2018-03-31 Filed 2018-06-28
S-1 2018-01-19 Public Filing
10-Q 2017-12-31 Filed 2018-02-14
10-Q 2017-09-30 Filed 2017-11-14
10-Q 2017-06-30 Filed 2017-08-10
10-K 2017-03-31 Filed 2017-06-28
10-Q 2016-12-31 Filed 2017-02-14
10-Q 2016-09-30 Filed 2016-11-17
10-Q 2016-06-30 Filed 2016-08-16
10-K 2016-03-31 Filed 2016-06-24
10-Q 2015-12-31 Filed 2016-02-16
10-Q 2015-09-30 Filed 2015-11-16
10-Q 2015-06-30 Filed 2015-08-14
10-K 2015-03-31 Filed 2015-06-25
10-Q 2014-12-31 Filed 2015-02-17
10-Q 2014-09-30 Filed 2014-11-14
10-Q 2014-06-30 Filed 2014-08-14
10-K 2014-03-31 Filed 2014-06-30
10-Q 2013-12-31 Filed 2014-02-14
10-Q 2013-09-30 Filed 2013-11-05
10-Q 2013-06-30 Filed 2013-08-13
10-K 2013-03-31 Filed 2013-05-20
10-Q 2012-12-31 Filed 2013-02-15
10-Q 2012-09-30 Filed 2012-11-13
10-Q 2012-06-30 Filed 2012-08-14
10-K 2012-03-31 Filed 2012-07-13
10-Q 2011-12-31 Filed 2012-02-14
10-Q 2011-09-30 Filed 2011-11-14
10-Q 2011-06-30 Filed 2011-08-15
10-K 2011-03-31 Filed 2011-07-14
10-Q 2010-12-31 Filed 2011-02-15
10-Q 2010-09-30 Filed 2010-11-01
10-Q 2010-06-30 Filed 2010-08-23
10-K 2010-03-31 Filed 2010-07-14
10-Q 2009-12-31 Filed 2010-02-16
8-K 2020-04-21 Officers
8-K 2019-06-27 Officers
8-K 2019-06-14 Leave Agreement, M&A
8-K 2019-05-08 Officers, Regulation FD, Exhibits
8-K 2019-04-22 Officers, Regulation FD, Exhibits
8-K 2019-01-24 Officers, Regulation FD, Exhibits
8-K 2019-01-18 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-11-21 Other Events, Exhibits
8-K 2018-11-15 Officers, Exhibits
8-K 2018-10-22 Enter Agreement, Exhibits
8-K 2018-10-19 Enter Agreement, M&A, Sale of Shares, Exhibits
8-K 2018-08-29 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-04-05 Other Events, Exhibits
8-K 2018-03-15 Other Events, Exhibits

Vitality Biopharma Financials

VBIO Metrics, Comps, Filings

Quarterly | Annual

Business

Unless otherwise provided in this Annual Report, references to the “Company,” “we,” “us”, and “our” refer to Vitality Biopharma, Inc., a Nevada corporation formed on June 29, 2007 and formerly known as Legend Mining Inc. On October 10, 2011, we completed a merger with our wholly-owned subsidiary, Stevia First Corp., whereby we changed our name from “Legend Mining Inc.” to “Stevia First Corp.” On July 15, 2016, our Board of Directors and shareholders approved a name change to Vitality Biopharma, Inc.

Vitality Biopharma is a company focused on the advancement of pharmaceuticals and innovative technologies that improve the lives of patients. We seek to achieve this objective through the development of novel cannabinoid pharmaceutical prodrugs known as cannabosides. We will conduct our operations using our own personnel and facilities, through subsidiaries established to conduct such operations, and through strategic partnerships with promising early stage companies that are bringing innovative products and services to market but lack the necessary capital or resources to fully capitalize on their high growth potential. We may provide assistance to such strategic partners through management assistance, loans of capital or equipment or personnel resources, or other arrangements designed to support the operations of our Company.

Our cannabosides are cannabinoid-glycoside prodrugs, which were discovered through application of the Company's proprietary enzymatic bioprocessing technologies, that are converted within the body after administration from an inactive molecule into a pharmacologically active drug. Currently, the Company has produced more than 25 novel cannabosides, including glycosylated tetrahydrocannabinol (THC), cannabidiol (CBD), cannabidivarin (CBDV) and cannabinol (CBN), that are covered by worldwide patent applications for composition of matter, method of production and method of use.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
RXI Pharmaceuticals (RXII) 7,253 0% -0.5 -194% 3,809 2,059 138 0 -7,398 -7,315 3,963
Ethema Health (GRST) 7,193 0% -1.2 -32% 23,469 33,429 599 0 -7,507 -6,127 7,192
Vivos (RDGL) 7,143 0% -7.6 -561% 197 1,390 8 0 -1,106 -971 7,400
Mikros Systems (MKRS) 7,118 61% -32.0 -4% 3,336 1,082 4,891 3,003 -132 -164 5,234
Pressure Biosciences (PBIO) 7,038 41% -1.9 -331% 2,411 12,035 1,530 630 -7,979 -3,691 6,902
MGT Capital Investments (MGTI) 7,028 -31% -0.6 -144% 5,265 1,955 190 -58 -7,582 -7,576 4,915
International Stem Cell (ISCO) 7,018 62% -5.0 -19% 8,260 4,636 6,635 4,138 -1,551 -1,322 6,555
Star Gold (SRGZ) 6,966 -29.3 -31% 751 35 0 0 -235 -235 6,865
Westmoreland Coal (WLB) 6,952 22% -73.7 -15% 1,467,857 2,190,755 1,264,675 282,069 -219,134 -13,208 973,082
Vaso (VASO) 6,906 54% -5.8 -7% 45,928 43,364 51,794 28,138 -3,037 -964 5,563
Scientific Industries (SCND) 6,822 43% 6.9 5% 8,863 2,553 10,165 4,402 447 801 5,562
Vitality Biopharma (VBIO) 6,792 0% -0.2 -324% 4,197 1,644 95 0 -13,584 -13,577 2,833
Avant Diagnostics (AVDX) 6,739 -3.1 -52% 4,907 3,030 0 0 -2,557 -2,262 6,910
Video Display (VIDE) 6,701 25% -52.2 -3% 9,802 5,465 13,711 3,469 -313 -119 6,215
Boston Therapeutics (BTHE) 6,668 0% -4.7 -207% 743 6,362 13 0 -1,537 -1,423 6,659
China Xuefeng Environmental (CXEE) 6,652 59% -1.6 6% 87,699 19,594 14,414 8,439 5,217 9,810 -16,127
Textmunication Holdings (TXHD) 6,569 61% -2.2 -559% 541 566 758 460 -3,023 -3,023 6,668
IIoT-OXYS (ITOX) 6,490 70% -4.6 -341% 491 2,218 114 80 -1,676 -1,552 7,096
ETF Managers Group Commodity Trust I (RISE) 6,472 6.4 12% 8,210 25 0 0 1,009 1,009 6,472
Global Digital Solutions (GDSI) 6,377 -2.2 -2,467% 83 5,129 0 0 -2,045 -2,866 6,326

Balance Sheet ($'000)2011-09-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash55175325335963921,1665511,8311,4038301,7821,0513901,1952089520341541,1535318151,3636561733377,4625,9834,6743,958
Accounts Receivable283940624377303928321925201314720461900
Inventory16193588866660
PP&E12
Assets58205358307915391,2826371,8851,4248831,8621,1354621,25229513569711961,1755598391,38267618336516,6146,0754,9174,197
Accounts Payable10388
Long-Term Debt6256256257626250
Liabilities2372425847761,1711,1082,2322,0971,6301,5351,4751,5431,6271,5422,1473796535839928778017465823993545187887461,0541,2481,644
Stockholders' Equity-179-222-4954-380-568-950-1,460254-110-591319-491-1,079-896-84-518-513-920-681374-187257982322-336-42315,8685,0213,6702,553
Income Statement ($'000)2011-09-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue00000004112860586281544646403127311925264495
Cost of Revenue1264206724315425212042201717232615
Gross Profit306539-938500212520-1171322122
R&D04212412310032229246234366312184161125110130255410407421563508587530112599328295
SG&A75351,0117985914717267017967465679336565937425353633287076709206746026195985236841,0271,415852727
Tax0000000000000000000000000
Net Income-84-44-1,184-866-587-970-899-782-1,045-1,427-656-1,019-1,142-843216-84-778-439-1,147-2,500-1,114-1,106-899-1,242-1,062-1,135-1,114-1,209-9,557-1,591-1,227
Cash Flow ($'000)2011-09-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-53-100-383-381-359-615-538-589-518-731-662-486-213-340-239-305-501-622-710-848-483-586-1,229-859-715
Cash Investing0000011000
Cash Financing156554451781,133011051,470001,2921002652524251,50009951,395-250